FDA Extends Review of Eisai, Biogen Alzheimer’s Drug
KEY POINTS
- FDA extends review of weekly subcutaneous LEQEMBI IQLIK for early Alzheimer’s initial treatment to Aug. 24, 2026
- Review delay follows a major amendment after an FDA request for additional information
- FDA has not raised concerns about approvability, while subcutaneous maintenance use was cleared in 2025
Eisai Co. and Biogen said the U.S. Food and Drug Administration has extended by three months its review of a supplemental biologics license application for weekly subcutaneous LEQEMBI IQLIK as an initial treatment for early Alzheimer’s disease.
The new Prescription Drug User Fee Act action date is Aug. 24, 2026, the companies said in a release on Thursday.
According to the release, the FDA requested additional information as part of its ongoing review and determined that the submission constituted a major amendment to the application, requiring extra time to complete the assessment. Eisai and Biogen said the agency has not, at this point, raised concerns about the approvability of LEQEMBI IQLIK for initial treatment.
The filing covers a once-weekly subcutaneous formulation of lecanemab, an anti-amyloid beta antibody marketed in the United States as LEQEMBI IQLIK. The companies said they believe a comprehensive clinical data package evaluating subcutaneous administration across multiple clinical trials and dosing regimens strongly supports the initial-treatment use.
The FDA review extension follows the agency’s approval on Aug. 26, 2025 of a subcutaneous maintenance dosing regimen for LEQEMBI IQLIK, according to the release. The companies said the current application seeks to expand use of the once-weekly subcutaneous formulation into initial treatment, following that approval.
The companies said the drug has been approved by regulators in more than 50 markets globally as a treatment option for early Alzheimer’s disease, reflecting what they described as broad regulatory confidence in the therapy.
A subcutaneous option could give patients and caregivers greater flexibility than intravenous infusion, which has been the standard delivery route for anti-amyloid Alzheimer’s therapies. Easier administration is widely seen as an important factor in expanding uptake in a disease area where regular clinic visits and monitoring can be burdensome.
Lecanemab is one of a small group of anti-amyloid therapies cleared for early Alzheimer’s disease, a class that has drawn close scrutiny from regulators, physicians and payers over clinical benefit, safety monitoring and practical access. In the United States, treatment decisions for such medicines typically involve specialist diagnosis and imaging or biomarker confirmation of amyloid pathology.
Eisai and Biogen said they will continue discussions with the FDA during the review. The companies added that they are working to bring the option to patients and care partners as quickly as possible in order to broaden flexibility and choice in anti-amyloid treatment.
According to the release, Eisai leads global development and regulatory submissions for lecanemab, while Eisai and Biogen co-commercialize and co-promote the medicine under Eisai’s final decision-making authority. The companies have collaborated on Alzheimer’s disease treatments since 2014.
If approved, the initial-treatment label expansion for LEQEMBI IQLIK would mark a further step in shifting lecanemab toward more convenient administration formats. The extended review, however, pushes back the expected decision and leaves physicians, patients and investors waiting until late August for regulatory clarity.
Originally published on ibtimes.co.jp
